Literature DB >> 3221328

Testing for the equality of area under the curves when using destructive measurement techniques.

A J Bailer1.   

Abstract

The area under a curve (AUC) of metabolite concentration or drug concentration over time has biological meaning in many situations, and the test of AUC equality among a set of different dosing regimens is often of interest. For the situation where the experimental unit must be sacrificed in order to obtain an estimate of the metabolite or drug concentration, it is noted that linear combinations of mean concentrations at time points for a particular dosing regimen can be used to estimate the AUC for that regimen. Contrasts among AUC estimates are readily constructed and tested within this derivation.

Mesh:

Year:  1988        PMID: 3221328     DOI: 10.1007/bf01062139

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  4 in total

Review 1.  Use of statistical methods in evaluation of in vivo performance of dosage forms.

Authors:  W J Westlake
Journal:  J Pharm Sci       Date:  1973-10       Impact factor: 3.534

2.  Bioavailability--a problem in equivalence.

Authors:  C M Metzler
Journal:  Biometrics       Date:  1974-06       Impact factor: 2.571

3.  A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation.

Authors:  K C Yeh; K C Kwan
Journal:  J Pharmacokinet Biopharm       Date:  1978-02

4.  The inhalation toxicity of two commercial dyes: solvent yellow 33 and solvent green 3.

Authors:  J D Sun; R F Henderson; T C Marshall; Y S Cheng; J S Dutcher; J A Pickrell; J L Mauderly; F F Hahn; D A Banas; F A Seiler
Journal:  Fundam Appl Toxicol       Date:  1987-04
  4 in total
  98 in total

1.  Construction of an optimal destructive sampling design for noncompartmental AUC estimation.

Authors:  F Vandenhende; M Comblain; M H Delsemme; W Dewe; W P Hoffman; B Boulanger
Journal:  J Pharmacokinet Biopharm       Date:  1999-04

2.  Variability of the model-independent AUC: the one sample per individual case.

Authors:  W Jawień
Journal:  J Pharmacokinet Biopharm       Date:  1999-08

3.  Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.

Authors:  Maite Verreault; Charlotte Schmitt; Lauriane Goldwirt; Kristine Pelton; Samer Haidar; Camille Levasseur; Jeremy Guehennec; David Knoff; Marianne Labussière; Yannick Marie; Azra H Ligon; Karima Mokhtari; Khê Hoang-Xuan; Marc Sanson; Brian M Alexander; Patrick Y Wen; Jean-Yves Delattre; Keith L Ligon; Ahmed Idbaih
Journal:  Clin Cancer Res       Date:  2015-10-19       Impact factor: 12.531

4.  Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis.

Authors:  Wai Kit Chew; Ignacio Segarra; Stephen Ambu; Joon Wah Mak
Journal:  Antimicrob Agents Chemother       Date:  2012-01-23       Impact factor: 5.191

5.  Estimation of AUC from 0 to Infinity in Serial Sacrifice Designs.

Authors:  Martin Josef Wolfsegger; Thomas Jaki
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

6.  Establishing bioequivalence in serial sacrifice designs.

Authors:  Martin J Wolfsegger
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-10-12       Impact factor: 2.745

7.  Comprehensive pharmacokinetic studies and oral bioavailability of two Mn porphyrin-based SOD mimics, MnTE-2-PyP5+ and MnTnHex-2-PyP5+.

Authors:  Tin Weitner; Ivan Kos; Huaxin Sheng; Artak Tovmasyan; Julio S Reboucas; Ping Fan; David S Warner; Zeljko Vujaskovic; Ines Batinic-Haberle; Ivan Spasojevic
Journal:  Free Radic Biol Med       Date:  2013-01-15       Impact factor: 7.376

8.  Bayesian approach to estimate AUC, partition coefficient and drug targeting index for studies with serial sacrifice design.

Authors:  Tianli Wang; Kyle Baron; Wei Zhong; Richard Brundage; William Elmquist
Journal:  Pharm Res       Date:  2013-10-03       Impact factor: 4.200

9.  Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model.

Authors:  Brioni R Moore; Kevin T Batty; Christopher Andrzejewski; Jeffrey D Jago; Madhu Page-Sharp; Kenneth F Ilett
Journal:  Antimicrob Agents Chemother       Date:  2007-11-05       Impact factor: 5.191

10.  Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.

Authors:  Rajendar K Mittapalli; Shruthi Vaidhyanathan; Arkadiusz Z Dudek; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2012-12-17       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.